The largest U.S. banks are scrutinizing members of the Federal Reserve for any insight into how the central bank will tinker interest rates.Banksread more
The U.S. and China restarted their trade talks, but signs are showing a comprehensive deal could be a long way off, if it happens at all.Marketsread more
U.S. President Donald Trump said Tuesday that Washington and Beijing have a long way to go on trade, adding that America could place tariffs on an additional $325 billion...Asia Marketsread more
Facebook's cryptocurrency project has already been met with skepticism from policymakers around the world.Technologyread more
Stone, 66, a notorious Republican political operative who has described himself as a "dirty trickster," had previously been dressed down by the judge for his public remarks...Politicsread more
Delta is gathering more data from customers than ever in hopes of avoiding customer service problems and increasing customer satisfaction, its CFO says.At Workread more
The Biden team's second-quarter Federal Election Commission filing shows that the campaign wrote a check of just over $5,300 on June 28 to Sheehan Associates for "strategic...2020 Electionsread more
See which stocks are posting big moves after the bell on July 16.Market Insiderread more
While the vote served as a show of solidarity for Democrats, it recommended no substantive penalty against Trump.Politicsread more
United Airlines' second-quarter profit tops estimates but questions about the 737 Max linger.Airlinesread more
Three civil rights groups filed a federal lawsuit on Tuesday challenging the Trump administration's new asylum rule, which bars asylum claims from most noncitizens who travel...Politicsread more
A high court judge ruled on Tuesday that an HIV pill to prevent infection can be funded by the state health service in England, in a victory for AIDS campaigners who have been calling for its widespread use.
So-called pre-exposure prophylaxis (PrEP) against HIV, using Gilead Sciences' medicine Truvada, can cut the risk of getting the virus during sex by more than 90 percent, according to clinical studies.
But NHS (National Health Service) England had argued it was not in a position to fund the medicine because PrEP was a preventative service and therefore the responsibility of local authorities.
The high court in London, however, ruled there was nothing to stop NHS England paying for the drug, which was recommended for preventative use by the European Medicines Agency last month.
The National AIDS Trust had brought the legal case, arguing that PrEP was a potential game-changer and was urgently needed in the UK, where more than 4,000 people acquire HIV annually.
Use of of PrEP is rising fast in the United States, where tens of thousands of people have filled prescriptions for Truvada to prevent infection.
Despite the win for the British AIDS campaigners, there is no guarantee that PrEP will now get automatic NHS funding.
NHS England said it planned to appeal the decision and, even it it loses again, PrEP would be have to be assessed against other priorities.
"Of course, this does not imply that PrEP - at what could be a cost of 10-20 million pounds ($13-26 million) a year - would actually succeed as a candidate for funding when ranked against other interventions," said Jonathan Fielden, NHS England's head of specialised commissioning.
"But in those circumstances, Gilead ... will be asked to submit better prices, which would clearly affect the likelihood that their drug could be commissioned."
Follow CNBC International on and Facebook.